Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development Updates

LA JOLLA, Calif.–(BUSINESS WIRE)—- $EQ #GVHD–Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the fourth quarter and full year 2021 and provided corporate and clinical development updates. “I’m proud of our team and the progress we have made since the beginning of last year,” said Bruce Steel, chief executive officer at Equi
Click here to view original post